Zydus Cadila gets DCGI nod for launch of its NCE for diabetes
New Delhi: Cadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes for launch in the country.
Drug Controller General of India (DCGI) has approved Lipaglyn to be used for treating `diabetic dyslipidemeia` for launch, the company said in a filing to BSE.
Commenting on the development Zydus Cadila Chairman and Manging Director Pankaj R Patel said: "Lipaglyn provides patients suffering from diabetic dyslipidemia the option for once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control."
It has always been our dream to take a molecule right from concept stage to its launch. Today we have realised this dream, he added.
Diabetic dyslipidemeia is a condition where a person is diabetic and has elevated levels of total cholesterol.
Shares of Cadila healthcare were today trading at Rs 780.85 per scrip in the afternoon trade on BSE, down 4.13 per cent from its previous close.
More from India
More from World
More from Sports
More from Entertaiment
- India successfully test fires futuristic Scramjet Rocket Engine
- Modi govt plans Rs 2,000 crore package for refugees from PoK
- Watch: Baloch, Sindhi leaders hold joint protest against CPEC in London
- India in Olympics: PM Modi forms task force to improve Indian sports
- Watch: President confers Khel Ratna to PV Sindhu, Sakshi, Dipa and Jitu Rai
- From Swift Dzire, to a BMW: It's dream come true, says PV Sindhu after receiving second car from Sachin Tendulkar
- Narendra Modi's big plan for PoK refugees in India – A Rs 2,000 crore package
- Kerala train derail: Services resume in Ernakulam-Thrissur route
- Meet Lachlan Smart – The Aussie teen who becomes youngest pilot to fly solo around the world!
- Suicide bombing kills 11 at Yemen army camp: Officials